Vol. 5 No. 1 (2025)
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image of the issue cover

Published January 30, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pembrolizumab (Keytruda), 100 mg/4 mL, vial solution for infusion.
  • Indication: In combination with fluoropyrimidine and platinum–containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.